The Readout Loud cover image

377: Melodrama at the FDA and the Pfizer-Novo bidding war

The Readout Loud

00:00

Why is MetSera so desirable despite many obesity startups?

Elaine explains MetSera's monthly-dosed GLP-1/amylin assets, lack of published competitive data, and Pfizer's need for market entry.

Play episode from 24:00
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app